Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma
https://iovs.arvojournals.org/article.aspx?articleid=2768349
Results : We found a significant correlation between midkine expression in primary uveal melanoma and overall survival. Patients with high midkine expression displayed only a 20% 5-year survival, whereas patients with low midkine levels displayed a 90% survival rate. (...)
Conclusions : Midkine is identified as a tumor cell survival factor that drives metastasis and therapeutic resistance, and could be exploited as a biomarker as well as therapeutic target in uveal melanoma.
- Forums
- ASX - By Stock
- Midkine News 2020
Midkine is a tumor cell survival factor that displays metastatic...
-
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online